13 Result(s)
within
Medicine & Public Health
Cancer Research
Oncology
**dong Jiang
-
Article
Open AccessA deep learning-driven discovery of berberine derivatives as novel antibacterial against multidrug-resistant Helicobacter pylori
Helicobacter pylori (H. pylori) is currently recognized as the primary carcinogenic pathogen associated with gastric tumorigenesis, and its high prevalence and resistance make it difficult to tackle. A graph neur...
-
Article
Open AccessAutosurv: interpretable deep learning framework for cancer survival analysis incorporating clinical and multi-omics data
Accurate prognosis for cancer patients can provide critical information for optimizing treatment plans and improving life quality. Combining omics data and demographic/clinical information can offer a more com...
-
Article
Open AccessCorrection: Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
-
Article
Open AccessDiscovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment
-
Article
Open AccessSYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
Genomic MET amplification and exon 14 skip** are currently clinically recognized biomarkers for stratifying subsets of non-small cell lung cancer (NSCLC) patients according to the predicted response to c-Met in...
-
Article
The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer
Anlotinib is an oral small-molecule multitarget tyrosine kinase inhibitor that hampers neovascularization thus providing antitumor effect. The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomiz...
-
Article
Open AccessBerberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota
Trimethylamine-N-oxide (TMAO) derived from the gut microbiota is an atherogenic metabolite. This study investigates whether or not berberine (BBR) could reduce TMAO production in the gut microbiota and treat athe...
-
Article
Open AccessAzvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients
Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase (RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into Phase III trial for COVID-19 patie...
-
Article
Open AccessOral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota
The phenylalanine–tyrosine–dopa–dopamine pathway provides dopamine to the brain. In this process, tyrosine hydroxylase (TH) is the rate-limiting enzyme that hydroxylates tyrosine and generates levodopa (l-dopa) w...
-
Article
Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials
The lethal effects of multiple antigen-specific cellular therapy (MASCT) may be enhanced by blocking PD-1 in vitro and vascular endothelial growth factor receptor 2 inhibitor (apatinib). We analyzed the pooled...
-
Article
Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells
To determine if inhibiting neuropilin-1 (NRP-1) affects the radiosensitivity of NSCLC cells through a vascular endothelial growth factor receptor 2 (VEGFR2)-independent pathway, and to assess the underlying me...
-
Article
Application of proton MR spectroscopy on evaluation of radiotherapy treated intracranial tumors
To evaluate the clinical application of proton magnetic resonance spectroscopy (1HMRS) in patients with radiotherapy treated intracranial tumors.
-
Article
Clinical study on concurrent and sequential therapy of intensity modulated radiation therapy (IMRT) combined with NP regimen chemotherapy in the treatment of middle and advanced non-small cell lung cancer
To evaluate the clinical effects of concurrent and sequential therapy for middle and advanced stage non-small cell lung cancer (NSCLC) useing IMRT combined with NP regimen chemotherapy.
